Marine Biotechnology Market Size 2026
By Axis Intelligence Research
Co-author: Sarah Mitchell | Last updated: October 27, 2026 | License: CC BY 4.0
Eight marine-derived medicines generated $6.29 billion in company-recognized revenue in their latest fiscal year, according to an Axis Intelligence Research ledger built from nine filings. That single pharmaceutical slice equals 108.5% of the lowest and 84.7% of the highest 2025 estimate published for the entire marine biotechnology market.
Quick Answer
How big is the marine biotechnology market in 2026? The verifiable core is pharmaceutical. Axis Intelligence Research finds that marine-derived drugs earned $6.29 billion in their latest fiscal year, from filings by Pfizer, Roche, Takeda, Jazz, Amarin, Eisai and GSK. 90.8% of that revenue comes from one molecule family, auristatin antibody-drug conjugates. The EU’s statistically measured blue biotechnology sector turned over €942 million in 2022.
Key Findings
- Axis Intelligence Research finds that eight marine-derived drugs generated $6.29 billion in company-recognized revenue in their latest fiscal year (2025 or FY ending March 2026).
- Axis Intelligence Research’s Marine Drug Scaffold Concentration Index (MDSCI) reads 8,283 out of 10,000, more than four times the 1,800 level US antitrust agencies call “highly concentrated.”
- Auristatin antibody-drug conjugates, a payload family descended from a sea-hare compound, account for 90.8% of tracked marine-drug revenue, per Axis Intelligence Research.
- There were 17 approved marine-derived pharmaceuticals and 29 clinical-stage compounds as of March 1, 2026, per Mayer et al. in Marine Drugs (April 2026).
- Only two pre-collection notifications for high-seas marine genetic resources had been filed under the BBNJ Agreement by October 27, 2026: Ireland (July 16) and the United Kingdom (October 13).
Why Do Marine Biotechnology Market Size Estimates Disagree?
Five commercial report publishers’ public summaries put 2025 marine or blue biotechnology revenue between $5.8 billion and $7.43 billion. That is a 28.1% spread for the same year, and none of the public summaries discloses which products are counted.
The definitions are the problem. “Marine biotechnology” can mean an oncology antibody-drug conjugate, a tonne of farmed seaweed, a fish-oil capsule or an enzyme sold to a detergent maker. A single top-down number blends all four without showing the arithmetic.
So Axis Intelligence Research went bottom-up on the one segment where audited numbers exist: approved medicines whose active ingredient traces to a marine organism. The result is a floor, not a ceiling. It excludes nutraceuticals, cosmeceuticals, enzymes, biomaterials and diagnostics, and it still lands inside the published range.
| Measure | Value | Year | Source |
|---|---|---|---|
| Lowest public 2025 market estimate | $5.8 billion | 2025 | Commercial report summary (undisclosed method) |
| Highest public 2025 market estimate | $7.43 billion | 2025 | Commercial report summary (undisclosed method) |
| Spread between estimates | 28.1% | 2025 | Axis Intelligence Research calculation |
| Marine-Derived Drug Revenue Ledger | $6.29 billion | Latest fiscal year | Axis Intelligence Research, from company filings |
| EU blue biotechnology turnover | €942 million | 2022 | European Commission, EU Blue Economy Report 2025 |
Jennifer Miller: The comparison that matters is not ledger versus estimate. It is what the estimates imply about everything else. If drugs alone account for $6.29 billion, a $5.8 billion “market” leaves nothing for algae ingredients, marine collagen or enzymes. Either those segments are tiny or the low estimates are not counting medicines at all. Neither reading is in the summaries, which is exactly why a buyer should ask for the product list before paying for the report.
How Much Revenue Do Marine-Derived Drugs Generate?
Axis Intelligence Research’s Marine-Derived Drug Revenue Ledger totals $6.29 billion across nine revenue lines, eight products and seven companies. Every line is company-reported revenue from an annual filing or results release, converted to US dollars at a disclosed rate.
Marine-Derived Drug Revenue Ledger (latest fiscal year)
| Drug (INN) | Marine origin family | Reporting company | Reported revenue | USD million | Source |
|---|---|---|---|---|---|
| Padcev (enfortumab vedotin) | Auristatin ADC | Pfizer | $1,940M (FY2025) | 1,940.0 | Pfizer revenue tables |
| Polivy (polatuzumab vedotin) | Auristatin ADC | Roche | CHF 1,470M (FY2025) | 1,770.0 | Roche FY2025 release |
| Adcetris (brentuximab vedotin) | Auristatin ADC | Takeda (ex-US/Canada) | ¥140.2B (FY to Mar 2026) | 929.9 | Takeda Form 6-K |
| Adcetris (brentuximab vedotin) | Auristatin ADC | Pfizer (US/Canada) | $907M (FY2025) | 907.0 | Pfizer revenue tables |
| Zepzelca (lurbinectedin) | Ecteinascidin alkaloid | Jazz Pharmaceuticals | $307.3M (FY2025) | 307.3 | Jazz FY2025 results |
| Vascepa (icosapent ethyl) | Fish omega-3 | Amarin | $182.8M product revenue (FY2025) | 182.8 | Amarin Form 10-K |
| Tivdak (tisotumab vedotin) | Auristatin ADC | Pfizer | $147M (FY2025) | 147.0 | Pfizer revenue tables |
| Halaven (eribulin) | Halichondrin macrolide | Eisai | ¥13.2B (FY to Mar 2026) | 87.6 | Eisai FY2025 reference data |
| Blenrep (belantamab mafodotin) | Auristatin ADC | GSK | £17M (FY2025) | 22.4 | GSK Form 20-F |
| Total | 6,294.0 | Axis Intelligence Research |
Conversion rates: CHF 0.8305 per USD and USD 1.3192 per GBP, the 2025 annual averages in the Federal Reserve’s G.5A release; ¥150.77 per USD, the April 2025–March 2026 average disclosed in Eisai’s FY2025 reference data.
Two products dominate. Padcev and Polivy together account for 58.9% of the ledger. Adcetris, counted across both of its licensors, adds $1,836.9 million.
Astellas also recognized ¥221.2 billion of Padcev revenue in its fiscal year ended March 2026, per its FY2025 results presentation. The ledger does not add it, because Astellas and Pfizer share Padcev’s economics and the filings do not separate the overlap cleanly. Adding it would push the total higher, so the $6.29 billion is the conservative reading.
Which marine drugs are growing and which are shrinking?
| Drug | Prior year | Latest year | Direction | Source |
|---|---|---|---|---|
| Padcev (Pfizer) | $1,588M | $1,940M | Up | Pfizer revenue tables |
| Polivy (Roche) | — | CHF 1,470M | Up 38% at constant exchange rates | Roche FY2025 release |
| Adcetris (Takeda) | — | ¥140.2B | Up 8.7% at actual rates | Takeda Form 6-K |
| Adcetris (Pfizer) | $1,089M | $907M | Down | Pfizer revenue tables |
| Tivdak (Pfizer) | $131M | $147M | Up | Pfizer revenue tables |
| Zepzelca (Jazz) | $320.3M | $307.3M | Down | Jazz FY2025 results |
| Vascepa (Amarin) | $204.6M | $182.8M | Down | Amarin Form 10-K |
| Halaven (Eisai) | ¥28.8B | ¥13.2B | Down 54.2% | Eisai FY2025 reference data |
Jennifer Miller: Halaven is the case study every marine-drug investor should keep open. The molecule, a synthetic analog of a sponge compound, lost more than half its revenue in one fiscal year once exclusivity ended. Marine origin did not protect it. Synthetic manufacturing, which solved the supply problem that sank earlier sea-derived candidates, also made generic entry straightforward. The supply moat and the patent moat are different things, and only one of them expires.
What Is the Marine Drug Scaffold Concentration Index (MDSCI)?
The Marine Drug Scaffold Concentration Index (MDSCI) is an Axis Intelligence Research metric that measures how dependent marine-drug revenue is on a single chemical family. It applies the Herfindahl-Hirschman Index, the standard concentration test used in antitrust review, to scaffold families instead of companies.
Baseline reading (2026 edition, latest fiscal year data): 8,283 out of 10,000.
How the MDSCI is calculated
MDSCI = Σ (scaffold family share of ledger revenue, in percent)²
| Scaffold family | Marine organism lineage | Ledger revenue (USD million) | Share | Share² |
|---|---|---|---|---|
| Auristatin ADCs (Padcev, Polivy, Adcetris ×2, Tivdak, Blenrep) | Sea hare / cyanobacterium (dolastatin lineage) | 5,716.3 | 90.82% | 8,248.3 |
| Ecteinascidin alkaloid (Zepzelca) | Tunicate | 307.3 | 4.88% | 23.8 |
| Fish omega-3 (Vascepa) | Fish | 182.8 | 2.90% | 8.4 |
| Halichondrin macrolide (Halaven) | Sponge | 87.6 | 1.39% | 1.9 |
| MDSCI | 6,294.0 | 100% | 8,283 |
Components are shown rounded; the index is computed on unrounded shares. Organism lineages follow the classification used by the Marine Pharmacology clinical pipeline, maintained by A.M.S. Mayer’s team at Midwestern University.
How to read the score
The 2023 Merger Guidelines published by the US Department of Justice and Federal Trade Commission state that markets with a Herfindahl-Hirschman Index above 1,800 are highly concentrated. The MDSCI baseline of 8,283 sits at more than four times that level. A score of 10,000 would mean one scaffold earns everything.
Jennifer Miller: An 8,283 reading says the ocean’s commercial contribution to medicine is, in revenue terms, one molecule family carried by five different antibodies. That is a strength and a fragility at once. Auristatin payloads are proven, licensable and endlessly re-targetable, which is why every big ADC developer reaches for them. But a safety signal, a payload-resistance pattern or a shift to newer payload classes would hit 90.8% of tracked revenue simultaneously. The index falls only when a non-auristatin marine drug becomes a commercial product at scale, and the trial data below suggests that is not imminent.
The MDSCI will be recomputed annually after full-year filings, with the next reading planned for the 2026 fiscal year.
How Many Marine-Derived Drugs Are Approved in 2026?
Seventeen marine-derived pharmaceuticals were approved for clinical use and 29 compounds were in Phase I, II or III trials as of March 1, 2026, according to Mayer and colleagues in Marine Drugs (published April 9, 2026). The same review counted 173 structurally defined marine compounds studied preclinically in 2022–2023, by research groups from 40 nations.
| Pipeline stage | Count | As of | Source |
|---|---|---|---|
| Approved marine-derived pharmaceuticals | 17 | March 1, 2026 | Mayer et al., Marine Drugs 24(4):133 |
| Compounds in Phase I–III | 29 | March 1, 2026 | Mayer et al., Marine Drugs 24(4):133 |
| Preclinical compounds reviewed (2022–2023) | 173 | 2022–2023 | Mayer et al., Marine Drugs 24(4):133 |
| Nations contributing preclinical research | 40 | 2022–2023 | Mayer et al., Marine Drugs 24(4):133 |
| Clinical-stage compounds per approved drug | 1.71 | March 1, 2026 | Axis Intelligence Research (29 ÷ 17) |
Approval counts in this field depend on inclusion rules. The Marine Pharmacology tracker lists a drug only when a direct structural route leads from a marine natural product to the medicine, and it removes drugs withdrawn by regulators to a separate list. Different rules produce different totals, which is why a review count and a news headline rarely match.
Which Marine Drugs Are in the Most Clinical Trials?
Axis Intelligence Research compiled the latest active US clinical trial counts for 18 approved marine-derived drugs from the update log of the Marine Pharmacology tracker. The total is 991 trials, with counts dated between July 2025 and October 4, 2026.
| Drug | Class | Active US trials | Count dated |
|---|---|---|---|
| Cytarabine | Nucleoside | 413 | Oct 4, 2026 |
| Enfortumab vedotin | ADC | 88 | Oct 4, 2026 |
| Disitamab vedotin | ADC | 82 | Oct 4, 2026 |
| Eribulin mesylate | Halichondrin analog | 81 | Oct 4, 2026 |
| Polatuzumab vedotin | ADC | 78 | Oct 4, 2026 |
| Brentuximab vedotin | ADC | 60 | Oct 4, 2026 |
| Belantamab mafodotin | ADC | 49 | Oct 4, 2026 |
| Becotutag vedotin | ADC | 46 | Oct 4, 2026 |
| Lurbinectedin | Ecteinascidin alkaloid | 33 | Oct 4, 2026 |
| Trabectedin | Ecteinascidin alkaloid | 15 | Jul 2026 |
| Omega-3-acid ethyl esters | Fish omega-3 | 12 | Jul 2026 |
| Eicosapentaenoic acid ethyl ester | Fish omega-3 | 8 | Oct 4, 2026 |
| Vidarabine | Nucleoside | 8 | Jul 2026 |
| Tisotumab vedotin | ADC | 5 | Jul 2025 |
| Telisotuzumab vedotin | ADC | 4 | Apr 2026 |
| Ziconotide | Cone-snail peptide | 4 | Oct 4, 2026 |
| Trastuzumab botidotin | ADC | 3 | Jul 2026 |
| Omega-3-carboxylic acid | Fish omega-3 | 2 | Jul 2026 |
Source: Marine Pharmacology update log; trial counts may include ongoing Phase 1, 2 and 3 studies.
Excluding cytarabine, a decades-old leukemia backbone used across hundreds of combination protocols, antibody-drug conjugates account for 415 of 578 active US trials. Axis Intelligence Research finds that 71.8% of active US trial activity for newer marine-derived drugs tests an antibody-drug conjugate.
Jennifer Miller: The trial table confirms what the revenue table implies. Clinical investigators are not betting on new marine scaffolds as much as on new targets for an old marine payload. Disitamab vedotin’s 82 US trials matter here: a Chinese-originated ADC now runs nearly as many US studies as Padcev. If any of those readouts lead to a US approval, the auristatin share of the ledger rises again.
How Much Algae and Seaweed Does the World Produce?
World aquaculture produced 141 million tonnes including algae in 2024, valued at $391 billion, according to FAO’s State of World Fisheries and Aquaculture 2026. Aquatic animals made up 103 million tonnes, worth $371 billion at the farm gate.
Subtracting the two FAO figures, Axis Intelligence Research estimates that farmed algae accounted for about 38 million tonnes and roughly $20 billion in farm-gate value in 2024.
| Indicator | 2024 value | Source |
|---|---|---|
| Global fisheries and aquaculture production | 235 million tonnes | FAO SOFIA 2026 |
| Aquaculture production including algae | 141 million tonnes | FAO SOFIA 2026 |
| Aquaculture value including algae | $391 billion | FAO SOFIA 2026 |
| Aquaculture aquatic animals | 103 million tonnes ($371 billion) | FAO SOFIA 2026 |
| Farmed algae (implied) | ~38 million tonnes | Axis Intelligence Research estimate (141 − 103) |
| Farmed algae farm-gate value (implied) | ~$20 billion | Axis Intelligence Research estimate (391 − 371) |
These are biomass figures, not biotechnology revenue. Most farmed seaweed is eaten or processed into commodity hydrocolloids. Only a small, unmeasured fraction becomes high-value biotech ingredients such as fucoidan, phycocyanin or marine-derived pharmaceutical excipients. The tonnage shows how much raw material exists; it does not show how much is upgraded.
How Big Is the EU Blue Biotechnology Sector?
The EU blue biotechnology sector generated €942 million in turnover and €327 million in gross value added in 2022, employing about 2,400 people, according to the European Commission’s EU Blue Economy Report 2025. Turnover rose 18% from 2021.
| Indicator (EU-27, 2022) | Value | Source |
|---|---|---|
| Turnover | €942 million | EU Blue Economy Report 2025 |
| Gross value added | €327 million | EU Blue Economy Report 2025 |
| Gross profit | €168 million | EU Blue Economy Report 2025 |
| Direct employment | ~2,400 | EU Blue Economy Report 2025 |
| Average annual wage | €66,300 | EU Blue Economy Report 2025 |
| Turnover per employee | €392,500 | Axis Intelligence Research (942M ÷ 2,400) |
| Germany’s share of sector GVA | 29% | EU Blue Economy Report 2025 |
| France’s share of sector GVA | 21% | EU Blue Economy Report 2025 |
How much investment does blue biotech attract in Europe?
European blue biotechnology closed 114 investment deals between 2018 and 2023, against 90 deals across 2000–2018, per the same Commission report. The deals totaled €405 million, with a mean of €5.1 million and a median of €1.3 million, mostly grants and early-stage rounds.
Jennifer Miller: Set the EU figure beside the drug ledger and the two measure entirely different things. The Commission counts firms classified as blue biotech; the ledger counts multinational oncology franchises whose payload happens to descend from a mollusk. Neither is wrong. But the €1.3 million median deal says European marine biotech is still financed like a research field, while the ADC revenue is booked by companies that would never describe themselves as “marine.” The value created by the ocean and the value captured by ocean-focused companies are not the same number.
What Does the High Seas Treaty Mean for Marine Biotechnology?
The BBNJ Agreement, the treaty on Biodiversity Beyond National Jurisdiction, entered into force on January 17, 2026, according to the United Nations. It sets rules for collecting marine genetic resources on the high seas and for sharing the benefits. Its first Conference of the Parties opens on January 11, 2027, at UN headquarters in New York.
Under article 12, parties must notify the treaty’s clearing-house before collecting marine genetic resources in areas beyond national jurisdiction. As of October 27, 2026, the UN notification register lists two pre-collection notifications:
| Interim reference | Notifying party | Date received |
|---|---|---|
| BBNJ-MGR-TEMP-2026-001 | Ireland | July 16, 2026 |
| BBNJ-MGR-TEMP-2026-002 | United Kingdom | October 13, 2026 |
Jennifer Miller: Two notifications in nine months is the baseline every benefit-sharing debate at COP1 will start from. Low numbers can mean two different things: that high-seas sampling for biotech is rare, or that most sampling is happening under flags whose states are not yet parties. The register cannot tell them apart. What it does establish is that the compliance paperwork for deep-sea bioprospecting now exists, has a date stamp and is public, which changes the due-diligence questions an investor can ask a marine-discovery startup.
Methodology
Ledger scope. The Marine-Derived Drug Revenue Ledger includes approved medicines listed by the Marine Pharmacology tracker whose reporting company discloses product-level revenue in an annual filing or full-year release. Each line is revenue recognized by the reporting company, not end-market sales. Products without product-level disclosure in a fetched primary document (including Aidixi, Yondelis, Lovaza and Prialt) are excluded rather than estimated.
Fiscal periods. Pfizer, Roche, Jazz, Amarin and GSK report calendar 2025. Takeda and Eisai report the fiscal year April 2025 to March 2026. Mixing the two shifts the window by one quarter for the Takeda and Eisai lines.
Currency. CHF and GBP lines use the Federal Reserve’s 2025 annual average rates (0.8305 CHF per USD; 1.3192 USD per GBP). JPY lines use ¥150.77 per USD, the April 2025–March 2026 average disclosed by Eisai, matching the Japanese fiscal period.
Overlap rule. Where two companies share one product’s economics and filings cannot separate them (Padcev at Pfizer and Astellas), only one company’s line enters the total. Adcetris appears twice because Pfizer and Takeda hold separate territories.
MDSCI. Each ledger line is assigned to a scaffold family by the marine natural product it derives from. Shares are family revenue divided by the ledger total, in percent; the index is the sum of squared shares (0–10,000). This baseline uses only the nine ledger lines; adding products later will change the denominator, and each reading will state its product list.
Trial counts. Each count is the most recent US figure stated for that drug in the Marine Pharmacology update log. Drugs not updated in October 2026 carry their last stated value and date.
Commercial estimates. The five 2025 market-size figures come from public report summaries with undisclosed methods. They are recorded in the dataset for reconciliation only and are not used in any Axis calculation except the spread and ledger ratios.
About This Dataset
The dataset behind this page contains 140 rows: company-reported revenue in native currency, conversion rates, the converted ledger, MDSCI components and reading, pipeline counts, per-drug trial counts, FAO aquaculture figures, EU blue biotechnology indicators and BBNJ treaty data. Every row carries its source organization, document, URL, retrieval date and a flag for Axis calculations, with the formula in method_note.
Download: marine-biotechnology-market-size.csv (CC BY 4.0). Reuse is free with attribution to “Axis Intelligence Research, Marine Biotechnology Market Size 2026.”
Questions About Marine Biotechnology, Answered With Data
Is the marine biotechnology market really worth $6–7 billion?
Commercial estimates for 2025 range from $5.8 billion to $7.43 billion, but none publishes its product list. Axis Intelligence Research’s filing-based ledger finds $6.29 billion from eight marine-derived drugs alone, so any estimate that also claims to cover algae ingredients, enzymes and cosmeceuticals should sit above that figure.
What is the best-selling drug that comes from the ocean?
Padcev (enfortumab vedotin) led the ledger with $1,940 million of 2025 revenue at Pfizer. Its cytotoxic payload, monomethyl auristatin E, belongs to the dolastatin lineage first isolated from a sea hare and linked to a cyanobacterium. Polivy followed at CHF 1,470 million at Roche.
Why are antibody-drug conjugates counted as marine drugs?
The Marine Pharmacology tracker lists a drug when a direct structural route connects it to a marine natural product. Auristatin payloads such as MMAE and MMAF qualify through dolastatin 10, so ADCs carrying them are counted even though the antibody itself is not marine.
Do marine-derived drugs keep their sales after patents expire?
Not automatically. Eisai’s Halaven, an analog of a sponge compound, fell 54.2% to ¥13.2 billion in the fiscal year ended March 2026 after exclusivity ended. Synthetic production removes supply constraints, which also makes generic competition easier.
Can companies still collect deep-sea organisms for drug discovery?
Yes, but high-seas collection now falls under the BBNJ Agreement, in force since January 17, 2026. Parties must file a pre-collection notification; the UN register listed two by October 27, 2026, from Ireland and the United Kingdom.
Which European countries lead blue biotechnology?
Germany generated 29% of EU blue biotechnology gross value added in 2022 and France 21%, per the European Commission’s EU Blue Economy Report 2025. The whole EU sector employed about 2,400 people.
How long does it take for a marine compound to become a medicine?
There is no single figure, but the ratio is telling: 29 compounds were in clinical trials for 17 approved drugs as of March 2026, per Mayer et al. That is 1.71 clinical candidates per approval, drawn from a preclinical pool of 173 compounds studied in 2022–2023 alone.
Is seaweed farming part of the marine biotechnology market?
Partly. FAO’s 2026 data implies about 38 million tonnes of farmed algae in 2024, worth roughly $20 billion at the farm gate, per an Axis Intelligence Research calculation. Most of that is food and commodity processing; only an unmeasured share becomes biotech ingredients.
Cite This Page
APA: Axis Intelligence Research, & Miller, J. (2026, October 27). Marine biotechnology market size 2026: What ocean-derived drugs actually earn. Axis Intelligence. https://axis-intelligence.com/marine-biotechnology-market-size/
MLA: Axis Intelligence Research, and Jennifer Miller. “Marine Biotechnology Market Size 2026: What Ocean-Derived Drugs Actually Earn.” Axis Intelligence, 27 Oct. 2026, axis-intelligence.com/marine-biotechnology-market-size/.
Chicago: Axis Intelligence Research, and Jennifer Miller. “Marine Biotechnology Market Size 2026: What Ocean-Derived Drugs Actually Earn.” Axis Intelligence, October 27, 2026. https://axis-intelligence.com/marine-biotechnology-market-size/.